Overall, our findings suggest that combined NOS and PI3K inhibition is capable of targeting chemoresistant and tumor-initiating population of breast cancer cells within MpBC tumors, leading to their increased chemosensitivity. This evidence concerns the gene NOS2 and breast carcinoma.